Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SH) Latest Company News

Oct 28, 2026, 09:03 UTC
Lianhuan Pharmaceutical reported revenue of 2.328 billion yuan and attributable net profit of 14.6596 million yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 28, 2026, 09:03 UTC
Lianhuan Pharmaceutical reported third-quarter 2026 revenue of 757 million yuan, down 4.99% year over year, and attributable net profit of 4.1378 million yuan, down 16.68%.
Source:
- finance.sina.cn
Oct 20, 2026, 08:53 UTC
Lianhuan Pharmaceutical said it received an approval notice for a supplemental application for vildagliptin tablets and became the drug’s marketing authorization holder; the approval number remains unchanged.
Source:
- finance.sina.cn
Aug 28, 2026, 09:49 UTC
Lianhuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 10.5218 million yuan, turning from a loss in the same period last year.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 11, 2026, 09:27 UTC
Lianhuan Pharmaceutical's board approved its subsidiary Lianhuan (Nanjing) Medical Technology to borrow 10 million yuan from related party Jiangsu Lianhuan Health Industry Management Development at an annual interest rate of 2.5% for up to 3 months.
Source:
- finance.sina.cn
Aug 11, 2026, 09:27 UTC
Lianhuan Pharmaceutical's board approved its subsidiary Sichuan Longyi Pharmaceutical to apply for a comprehensive credit line of up to 271 million yuan from banks, effective until the 2026 annual shareholders' meeting.
Source:
- finance.sina.cn
Jul 21, 2026, 08:38 UTC
Lianhuan Pharmaceutical and its subsidiary Lianhuan Marketing signed project entry contracts with Yangzhou High-tech Zone Management Committee for two investment projects totaling 450 million yuan.
Source:
- finance.sina.cn

600513.SH

Lianhuan Pharmaceutical reported revenue of 2.328 billion yuan and attributable net profit of 14.6596 million yuan for the first three quarters of 2026.

Lianhuan Pharmaceutical reported third-quarter 2026 revenue of 757 million yuan, down 4.99% year over year, and attributable net profit of 4.1378 million yuan, down 16.68%.

Lianhuan Pharmaceutical said it received an approval notice for a supplemental application for vildagliptin tablets and became the drug’s marketing authorization holder; the approval number remains unchanged.

Lianhuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 10.5218 million yuan, turning from a loss in the same period last year.

Lianhuan Pharmaceutical's board approved its subsidiary Lianhuan (Nanjing) Medical Technology to borrow 10 million yuan from related party Jiangsu Lianhuan Health Industry Management Development at an annual interest rate of 2.5% for up to 3 months.

Lianhuan Pharmaceutical's board approved its subsidiary Sichuan Longyi Pharmaceutical to apply for a comprehensive credit line of up to 271 million yuan from banks, effective until the 2026 annual shareholders' meeting.

Lianhuan Pharmaceutical and its subsidiary Lianhuan Marketing signed project entry contracts with Yangzhou High-tech Zone Management Committee for two investment projects totaling 450 million yuan.